Axsome Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:AXSM) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 18.63 M26.2 M43.38 M32.42 M-1.05 M18.65 M 93.41 M Cash from investing activities 90 K30 K338 K13 K58 K71 K 480 K Cash from financing activities 30.41 M14.24 M29.27 M34.54 M21.27 M16.39 M 101.47 M Free cash flow 18.54 M26.17 M43.04 M32.41 M-1.1 M18.58 M 92.92 M

News

Stock Market Can't Hold Key Levels Amid AI Concerns; Nvidia Tumbles Despite Strong Earnings: Weekly Review

Construction Star Leads 11 Hot Stocks To Various Best Growth Lists like IBD 50, Sector Leaders

AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

UBS raises Axsome Therapeutics stock price target on sales force expansion

Wolfe Research initiates Axsome stock with outperform rating

RBC Capital raises Axsome Therapeutics price target on earnings

Axsome doses first patient in depression trial with solriamfetol

Guggenheim raises Axsome stock price target to $220 on strong sales

Axsome Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:AXSM) 2026-02-23

Truist reiterates Buy on Axsome stock ahead of April regulatory decision

TD Cowen raises Axsome stock price target to $215 on Auvelity growth

Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript